

STIC-ILL

From: STIC-Biotech/ChemLib  
Sent: Thursday, April 29, 2004 12:01 PM  
To: STIC-ILL  
Subject: FW: 09/899300

*Re: 1/28 NO 4/29*

*493865*

-----Original Message-----

From: Yaen, Christopher  
Sent: Thursday, April 29, 2004 11:44 AM  
To: STIC-Biotech/ChemLib  
Subject: 09/899300

could you please get the following ref(s):

Cancer Immunol Immunother. 1990;32(3):185-90.

Cancer Immunol Immunother. 1990;31(4):231-5.

Cancer Immunol Immunother. 1992;35(3):158-64.

Med Oncol Tumor Pharmacother. 1993;10(1-2):61-70.

Cancer Immunol Immunother. 1995 Jun;40(6):367-75.

Cancer Immunol Immunother. 1996 Feb;42(2):81-7.

Clin Cancer Res. 1998 Aug;4(8):1921-9.

Int J Pancreatol. 1997 Feb;21(1):43-52.

Hybridoma. 1988 Oct;7(5):429-40.

Jpn J Cancer Res. 1990 Mar;81(3):266-71.

Christopher Yaen  
US Patent Office  
Art Unit 1642  
571-272-0838  
REM 3A20  
REM 3C18

*13853578*

## A phase II trial of murine monoclonal antibody 17-1A and interferon- $\gamma$ : clinical and immunological data\*

Mansoor N. Saleh<sup>1, 2</sup>, Albert F. LoBuglio<sup>1</sup>, Richard H. Wheeler<sup>1</sup>, Kimberly J. Rogers<sup>1</sup>, Amy Haynes<sup>1</sup>, Jeannette Y. Lee<sup>1</sup>, and M. B. Khazaei<sup>1, 2</sup>

<sup>1</sup> The Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Ala., and <sup>2</sup> Veterans Administration Medical Center, Birmingham, Ala., USA

Received 23 May 1990/Accepted 9 August 1990

**Summary.** A group of 15 patients with metastatic colorectal adenocarcinoma received a combination of interferon  $\gamma$  (0.1 mg/m<sup>2</sup>, days 1–15) and the murine monoclonal antibody 17-1A (400 mg, days 5, 7, 9 and 12). The treatment was tolerated with minimal toxicity. Of the 14 evaluable patients, 13 developed human antibody to murine 17-1A, with 11 patients demonstrating antibody to the variable region of 17-1A (anti-idiotypic). Antibody to the variable region was inhibited by 17-1A but not by mouse immunoglobulin. Sera from patients with substantial anti-idiotypic reactivity were capable of inhibiting the binding of murine 17-1A to antigen expressing LS174-T cells thus indicating the presence of antibody directed against the 17-1A combining site (mirror-image anti-idiotypic). The median survival of the whole group was 56 weeks and there was no correlation between clinical response/survival and the development of anti-idiotypic antibody.

### Introduction

Over the past decade, a variety of murine monoclonal antibodies have entered phase I and II clinical trials. Several studies have reported clinical antitumor effects [19, 17, 30] but other studies have had little, if any, clinical responses [3, 14, 24]. Tumor heterogeneity [8], inadequate delivery of antibody to tumor target [7], suboptimal effector cell function in vivo [1] and the development of human antibodies against mouse mAbs [9, 23] have been cited as some of the possible causes for the poor clinical responses, despite well documented anti-tumor activity of the mAb in

vitro [6, 27]. The effect of unconjugated murine mAb is primarily mediated via the stimulation of the immune effector arm following binding to the tumor target. Biological agents that can enhance the expression of tumor surface antigens and/or enhance human effector cell function offer the opportunity to improve the therapeutic effectiveness of unconjugated monoclonal antibodies. When administered in combination, these reagents may potentially be synergistic in vivo. A number of in vitro studies [4, 25, 31] as well as some recent in vivo data [22] have documented the ability of interferon  $\gamma$  (IFN $\gamma$ ) to increase the expression of tumor-associated antigens. IFN $\gamma$  has also been shown to potentiate the cytolytic function of peripheral blood effector cells in vitro [20, 29] and in vivo [32].

We have previously reported on a phase I trial of murine 17-1A monoclonal antibody, which documented that 2-h infusions of 400 mg administered four times over an 8-day period resulted in continuous serum levels of 17-1A varying between 120–140  $\mu$ g/ml (peak) and 10–24  $\mu$ g/ml (nadir) during a 10-day period [9]. The treatment was well tolerated and no anti-(mouse mAb) response was noted during the 10 days of therapy. A phase I trial of recombinant IFN $\gamma$  (Genentec, Inc.) documented that a dose of 0.1 mg/m<sup>2</sup> was well tolerated and enhanced mononuclear cell function [21]. We have carried out a trial using the above IFN $\gamma$  regimen and this dose and schedule of 17-1A in a phase II trial in metastatic colon cancer.

### Materials and methods

**Patient selection.** The protocol was designed to treat patients with objectively measurable, metastatic gastrointestinal adenocarcinoma, who have high performance status ( $\geq 60$ , Karnofsky). All patients in this study had pathologically proven colon or rectal adenocarcinoma with small to moderate tumor burden as defined previously [4] and progressive disease; they had received no more than one previous trial of chemotherapy. Patients with prior chemotherapy were registered no sooner than 4 weeks from the last chemotherapy administration. Laboratory selection criteria included normal creatinine and bilirubin levels and alkaline phosphatase, serum glutamic-oxaloacetic transaminase, and glutamate-pyruvate transaminase not exceeding three times the normal levels. All patients signed

\* Supported by the Veterans Administration Medical Center and by Public Health Services grant CA 45232 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services

Offprint requests to: M. N. Saleh, Comprehensive Cancer Center, University of Alabama at Birmingham, Wallace Tumor Institute-262, Birmingham, AL 35294, USA

**Table 1.** Colon cancer patient characteristics

Patient	Metastatic sites	Tumor burden	KPS(%) <sup>a</sup>	Prior therapy
1	Lung	Moderate	90	RT/chemo
2	Lung/liver	Small	100	RT
3	Lung	Small	100	Chemo
4	Prostate	Small	80	Chemo
5	Lung/liver	Moderate	100	Chemo
6	Lung/liver	Small	100	None
7	Lung/liver	Moderate	60	Chemo
8	Liver	Small	60	Chemo
9	Liver	Small	60	Chemo
10	Lung/liver	Moderate	80	None
11	Pancreas/abdomen	Small	100	None
12	Abdomen	Small	100	Chemo
13	Liver	Small	100	Chemo
14	Liver	Small	100	None
15	Pancreas/liver	Moderate	90	Chemo

<sup>a</sup> Karnofsky performance status

an informed consent form approved by the Institutional Review Board. The protocol was conducted in accordance with an Investigational New Drug application submitted to the Food and Drug Administration.

**Treatment plan.** All patients received IFN $\gamma$  at a dose of 0.1 mg/m<sup>2</sup> ( $2 \times 10^6$  U/m<sup>2</sup>) daily for 15 days (days 1–15). Patients also received 400 mg mAb 17-1A mid-cycle on days 5, 7, 9 and 12.

All patients had follow-up for 8 weeks, at which time they were re-evaluated for evidence of objective response or disease progression. The criteria for response were as follows: *complete remission*, complete disappearance of all measurable lesions; *partial response*, >50% reduction in the sum of the products of the diameters of all measurable lesions; *progressive disease*, >50% increase in the products of the diameters of all measurable lesions or clinical evidence of disease progression, i.e., decrease in performance status or increase in symptoms; and *stable disease*, failure to meet criteria for partial response or disease progression. All patients with stable disease or objective response were continued on the protocol without alternative therapy until they fulfilled the criteria for progressive disease. Survival was measured from the date of registration in the study. Patient accrual took place from June 1986 to June 1988 and follow-up was completed through March 1989.

**17-1A infusions.** The 17-1A was provided by Centocor, Inc. (Malvern, Pa), in a solution of 10 mg/ml in 5-ml vials and stored at 4°C prior to use. The antibody was diluted in 200 ml saline for administration. All infusions were performed in the General Clinical Research Unit. All patients had a main i.v. access established in one arm and a heparin-lock vascular access in the other arm for blood sampling. The antibody preparation was piggybacked through a freely running i.v. access to allow independent control of the antibody infusion. All patients received an i.v. test dose of 0.7 mg with 30 min of careful monitoring for evidence of allergic reaction. If no adverse effect resulted from the test dose, the 400-mg treatment dose was infused over 120 min, and vital signs were determined four times at 15-min intervals, four times at 30-min intervals, or more frequently if problems arose.

**IFN $\gamma$  therapy.** Recombinant IFN $\gamma$  (Genentec Inc.) was provided as a sterile lyophilized powder with >98% purity and a specific activity of approximately  $2 \times 10^7$  units/mg protein on the basis of anti-viral activity using NIH reference standard for IFN $\gamma$ . The drug was reconstituted in physiological saline at a concentration of 0.1 mg/ml and administered as an intramuscular injection. Vital signs and systemic symptoms were monitored daily prior to each injection. On a day of 17-1A infusion, the IFN $\gamma$  was administered 4 h following the antibody infusion.

**Patient monitoring.** Patients had a complete blood count, chemistry profile and clinical evaluation on day 1 (prior to IFN $\gamma$  therapy), day 5

(prior to initiating 17-1A therapy), day 12 (last day of 17-1A therapy), day 15 (last day of IFN $\gamma$  therapy) and at 2-week intervals for a total of 8 weeks at which time a complete follow-up evaluation was performed.

**Human immune response.** Human antibodies to murine 17-1A and to the variable region of 17-1A (anti-idiotypic) were assayed using the "double-antigen" system previously described [16]. Polystyrene beads (Precision Plastic Ball, Chicago, Ill.) were coated with murine 17-1A and stored in phosphate-buffered saline/bovine serum albumin (PBS/BSA). Murine 17-1A or chimeric mouse/human 17-1A were radiolabeled with <sup>125</sup>I by the chloramine-T bead technique. The assay was performed in triplicate and consisted of incubation of a single 17-1A-coated bead with 100  $\mu$ l test serum on a shaker for 60 min at room temperature. This was followed by a single 5-ml wash using PBS/BSA and an incubation with 100  $\mu$ l <sup>125</sup>I-labeled 17-1A or <sup>125</sup>I-labeled chimeric 17-1A (2  $\mu$ g/ml;  $\approx 200,000$  cpm). Unbound radiolabeled antibody was washed off and the radioactivity bound to the bead was counted in a micromedic automatic gamma counter. Results obtained as mean cpm/head were converted to ng antibody using the specific activity of <sup>125</sup>I-labeled 17-1A or chimeric 17-1A and expressed as ng antibody bound/ml patient serum. Each serum sample was assayed for binding of murine and chimeric 17-1A in the same assay to compare reactivity with the whole antibody or the variable region (anti-idiotypic).

Sera from 38 patients with colorectal cancer never exposed to 17-1A were used to define the normal range of this assay system. The values for binding of murine 17-1A were  $4.8 \pm 2.4$  ng/ml and for chimeric 17-1A were  $2.8 \pm 1.0$  ng/ml. Thus, a positive assay result was defined as >10 ng/ml for murine 17-1A and >5 ng/ml for chimeric 17-1A.

To confirm the anti-variable-region specificity of selected sera, competitive inhibition studies were carried out using normal mouse immunoglobulin (Ig). For these studies, a 200-fold excess (40  $\mu$ g) unlabeled 17-1A or normal mouse Ig was added to the incubation of patient sera with the 17-1A-coated bead in step 1 of the above assay and then the assay completed as described above with <sup>125</sup>I-labeled murine 17-1A. The difference between inhibition by 17-1A and mouse Ig reflects antibody binding due to antibody to the variable region of 17-1A (anti-idiotypic antibody). For these studies, a rabbit antiserum to 17-1A F(ab)<sub>2</sub> served as a positive control while human serum containing antibody to a melanoma-reactive murine monoclonal antibody served as a negative control [14].

We also examined selected sera for the presence of "mirror-image" anti-idiotypic reactivity by determining the ability of patient sera to inhibit the binding of 17-1A to a colon cancer cell line that expresses the 17-1A antigen. A sample of 100 ng <sup>125</sup>I-labeled 17-1A (100  $\mu$ l) was incubated with  $1 \times 10^6$  LS-174T colon cancer cells in the presence of 10  $\mu$ l pre-therapy or post-therapy patient sera at 37°C for 60 min (total volume 175  $\mu$ l). Duplicate 70- $\mu$ l samples of the mixture were layered on top of 15% isotonic Percoll in a microfuge tube and centrifuged at 10,000 g for 5 min. The cell button with bound <sup>125</sup>I-labeled 17-1A was counted and the number of molecules of 17-1A bound per cell calculated from the number of cells per tube and the specific activity of the <sup>125</sup>I-labeled 17-1A [16]. The tumor cells incubated with <sup>125</sup>I-labeled 17-1A in the presence of pre-therapy sera bound 16,000–20,000 molecules of 17-1A per tumor cell. The percentage inhibition of the <sup>125</sup>I-labeled 17-1A binding to tumor cells by post-therapy serum as compared to pre-therapy serum was calculated as a measure of human antibody binding to the 17-1A antigen-binding site (mirror-image anti-idiotypic antibody). Sera not containing anti-(variable region) antibody activity ( $n = 15$ ) were tested and produced <30% inhibition (mean  $\pm 2$  SD). A positive assay was therefore defined as inhibition of >30%.

## Results

### Patient characteristics

The clinical characteristics of the patients are summarized in Table 1; 15 patients with metastatic colon cancer underwent treatment, 10 patients had a small tumor burden




Fig. 1. Mean white blood cell profile of patients receiving 17-1A + interferon  $\gamma$  for the treatment of metastatic colorectal cancer

Table 2. Human immune response to murine and chimeric 17-1A

Patient	Response (ng/ml) <sup>a</sup>				
	Pre-treatment	Week 2	Week 3	Week 6	Week 8
1	5/3	9/4	8/4	9/ 4	9/ 4
2	8/5	7/5	8/5	13/ 5	16/ 5
3	6/4	33/6	25/6	31/ 7	0/ 0
4	7/4	11/5	15/6	9/ 5	0/ 0
5	5/3	7/4	18/3	43/16	92/ 40
6	5/5	10/5	38/7	452/90	651/221
7	6/4	74/4	86/9	24/ 5	43/ 7
8	6/4	7/4	68/9	16/ 5	17/ 6
9	7/4	43/8	17/5	12/ 5	11/ 5
10	6/4	23/4	61/7	172/22	526/146
11	0/0	16/4	13/5	19/ 4	23/ 4
12	14/3	24/7	11/5	12/ 6	23/ 14
13	5/4	8/4	0/0	10/ 5	13/ 7
14	6/5	6/5	6/6	0/ 0	16/ 10

<sup>a</sup> Results are expressed as ng murine 17-1A/chimera 17-1A bound per ml sera (see Materials and methods)

(measurable lesions <5 cm in diameter) while 5 patients had moderate disease (measurable lesions 5–10 cm in diameter). Two-thirds of patients had a Karnofsky performance status of 90%–100% and all but 4 patients had received prior therapy. All 15 patients are evaluable for toxicity. One patient refused follow-up evaluation at 8 weeks and is excluded from response analysis.

### Toxicity

The most common side-effect was flu-like symptoms consisting of mild fever, malaise and arthralgias noted in 14/15 patients following IFN $\gamma$  therapy. Symptoms were tolerable (grades I–II) and subsided within 24 h following completion of IFN $\gamma$  therapy. One patient developed temporary blurred vision during therapy. The symptoms lasted for 48 h and resolved spontaneously without any modification in treatment. No other neurological symptoms were observed. Out of 15 patients, 5 noted gastrointestinal symptoms associated with 17-1A therapy. Symptoms con-

Table 3. Competitive inhibition of serum antibody reactivity to murine 17-1A

Serum source	Sample time (week)	Inhibitor <sup>a</sup>		
		None	17-1A	MIg
Patient 5	Pre	4	3	3
	3	14	6	8
	4	14	4	7
	6	23	4	18
	8	57	4	48
Patient 6	Pre	7	4	3
	3	30	3	12
	4	81	5	33
	6	407	7	153
	8	546	8	368
Patient 10	Pre	6	4	3
	3	46	7	16
	4	30	5	8
	6	116	6	26
	8	425	7	161
3196 <sup>b</sup>		312	6	180
DR <sup>b</sup>		186	6	7

<sup>a</sup> Results expressed as ng murine 17-1A bound/ml serum (see Materials and methods). Patient sera were incubated with no competing substance (None), 40  $\mu$ g murine 17-1A (17-1A) or 40  $\mu$ g normal mouse immunoglobulin (MIg)

<sup>b</sup> 3196 is a rabbit anti-17-1A F(ab)<sub>2</sub> and DR is a human anti-melanoma monoclonal antibody serum

sisted of mild (grades I–II) nausea/vomiting and/or diarrhea. In all cases, symptoms subsided within 24–48 h of onset.

### Laboratory studies

All patients developed a reduction in white blood cells by day 5 with spontaneous resolution following completion of IFN $\gamma$  therapy. The mean white blood cell count fell by 30%. This appeared to be selectively due to a reduction in neutrophils. The proportion of lymphocytes and monocytes remained unchanged throughout this period (Fig. 1). None of the patients developed absolute neutropenia (granulocytes <500/mm<sup>3</sup>). A similar though less pronounced reduction in platelet count was also noted. No other abnormalities in laboratory studies were noted.

### Immune response

Serial serum samples were available from 14 of the 15 patients. Table 2 provides the sera reactivities with murine 17-1A. One patient (no. 12) had a pretherapy value exceeding 10 ng/ml. Out of 14 patients, 13 developed a positive assay following 17-1A therapy. Antibody levels were low (10–25 ng/ml) in 6 patients (nos. 2, 4, 11, 12, 13, 14), moderately elevated (26–100 ng/ml) in 5 patients (nos. 3, 5, 7, 8, 9) and high (>100 ng/ml) in 2 patients (nos. 6, 10). Two patterns of peak antibody response were seen: 5 patients (nos. 3, 4, 7, 8, 9) achieved their peak

**Table 4.** Inhibition of  $^{125}$ I-labeled 17-1A binding to tumor cells by patient sera

Sample time (week)	inhibition (%) <sup>a</sup> by sera from patient				
	1	5	6	10	11
2	13	13	0	0	18
3	0	7	33	9	2
6	0	33	97	23	2
8	0	69	100	50	6

<sup>a</sup> Results expressed as percentage inhibition of  $^{125}$ I-labeled 17-1A binding to LS-174T colon cancer cells by post-therapy serum compared to pre-therapy serum (Patient nos. 1, 5, 6, 10, 11). Significant inhibition is >30% (see Materials and methods)

**Table 5.** Response characteristics

Patient	Toxicity <sup>a</sup>	Response	Survival (weeks)	Immune response	anti-idiotypic response
1	Flu/GI	P	56	None	None
2	Flu/GI	P	80	Low	None
3	GI	P	56	Moderate	Low
4	Flu	NA	60	Low	Low
5	Flu	S	40	Moderate	Moderate
6	Flu	P	56	High	High
7	Flu	S	60	Moderate	Low
8	Flu	P	24	Moderate	Low
9	Flu/GI	P	40	Moderate	Low
10	Flu	P	80	High	High
11	Flu	P	12	Low	None
12	Flu	S	72	Low	Low
13	Flu/GI	P	68	Low	Low
14	Flu	P	44	Low	Low
15	Flu	P	24	NA	NA


<sup>a</sup> Flu, influenza-like symptoms; GI, gastrointestinal symptoms; P, disease progression; S, stable disease; NA, data not available

response early (2–3 weeks) while 7 patients (nos. 2, 5, 6, 10, 11, 13, 14) had their peak response late (6–8 weeks). Indeed, patients 2, 13 and 14 would have been categorized as not having achieved an antibody response if only examined 2 and 3 weeks following therapy.

Table 2 also provides the serum antibody reactivity to chimeric 17-1A in these same samples. All patients had values  $\leq 5$  ng/ml prior to therapy. Eleven patients developed a positive assay following therapy with 17-1A and these positive assays coincided with the peak reactivity to murine 17-1A. The 3 patients (nos. 5, 6, and 10) with the largest anti-idiotypic response were also those patients with the highest reactivity to murine 17-1A. All 3 of these patients were in the category of late antibody responders achieving their peak response at week 8.

Sera of these 3 patients were also studied by assaying for competitive inhibition by mouse Ig to define anti-idiotypic reactivity. As illustrated in Table 3, there was excellent correlation between high serum binding of murine 17-1A in the presence of competing mouse Ig and the serum binding of chimeric 17-1A in Table 2 confirming the anti-(variable region) specificity of the antibody response.

Mirror-image anti-idiotypic reactivity (Table 4) was examined in 2 patients with no anti-idiotypic reactivity (nos. 1 and 11) and 3 patients with the highest anti-idiotypic reac-

**Fig. 2.** Overall survival of patients with metastatic colorectal cancer treated with murine monoclonal antibody 17-1A or 17-1A plus interferon  $\gamma$ 

tivity (nos. 5, 6 and 10). All 3 patients with high anti-idiotypic reactivity produced inhibition of 17-1A binding to colon cancer cells. Serial dilution of week-8 serum samples from patients 5, 6 and 10 had significant inhibition of binding at dilutions out to 1:32, 1:64 and 1:64, respectively (data not shown).

### Clinical response

Of the 14 evaluable patients, 3 had disease stabilization at 8 weeks (nos. 5, 7 and 12) and survived 40, 60 and 72 weeks, respectively. Eleven patients progressed on therapy. Their survival ranged from 12 to 80 weeks (Table 5). Figure 2 shows the overall survival of the study population, which was not significantly different from our previous experience in 25 patients treated with varying doses of 17-1A alone. The median survival for this study group was 56 weeks as compared to 57 weeks in the prior study [4].

### Discussion

Our study demonstrates that the combination of IFN $\gamma$  and mAb 17-1A is well tolerated and associated with minimal toxicity. The toxicity of the combined modality followed the predictable side-effects noted with either of the agents administered individually [12, 11]. The infusion of 17-1A over a 2 h period significantly reduced the acute gastrointestinal toxicity previously noted when the antibody was delivered more rapidly [15]. The reduction of peripheral blood granulocytes and platelets with sparing of the monocytes and lymphocytes has been previously noted with IFN $\alpha$  as well as IFN $\gamma$ . The etiology of this early onset granulocytopenia/thrombocytopenia does not appear to be due to bone marrow suppression [2] but may be related to events outside the marrow cavity. This is supported by the rapid reversibility following cessation of IFN $\gamma$  therapy noted in this as well as other studies [11, 2].

In our previously reported phase I study using 17-1A alone, 21 of 25 patients developed an anti-(mouse mAb) response including all five patients who received the identical dose and schedule of 17-1A used in this trial. A

similar frequency of anti-(mouse mAb) response occurred in this combination regimen of IFN $\gamma$  and 17-1A with 13 of 14 patients developing a response. We would conclude that this large dose (1.6 g) of antibody and high circulating blood levels of 17-1A for 10 days provided no evidence for induction of tolerance. The addition of IFN $\gamma$  to the regimen did not dramatically change the anti-(mouse mAb) response, although direct comparison of the two trials is limited by differences in dose and schedule of 17-1A.

A second aspect of the immune response relates to the human antibody response to the variable region of the 17-1A monoclonal antibody, i.e. anti-idiotypic response. We have recently described the use of chimeric mouse/human monoclonal antibody molecules, which have the variable region of the murine monoclonal reagent in the absence of murine constant region, as a convenient reagent for detection of anti-idiotypic (i.e. anti-variable-region) reactivity. As depicted in Table 2, the simultaneous measurement of murine and chimeric 17-1A reactivity allows one to quantify the proportion of antibody response directed to the variable region or constant regions of the molecule. Some degree of variable-region response were seen in 11 of 14 patients although many were of modest extent. Three patients developed relatively large amounts of anti-idiotypic antibodies. This occurred in the 3 patients who had the largest amount of anti-(mouse mAb) in this series and were characterized by having a late surge of antibody response (6–8 weeks) containing both constant- and variable-region specificity. Prior studies have also suggested that anti-idiotypic responses may occur in the later phases of the human immune response to monoclonal antibodies [10]. The clinical response and survival of patients did not correlate with the presence or absence of anti-idiotypic responses in general and the 3 patients with the highest levels of anti-idiotypic response had a clinical course similar to that of the remaining patients (Table 5). The inability of polyclonal mouse Ig to block serum antibody binding to murine 17-1A confirms that these sera had antibody reactivity specific to the variable region of 17-1A and the results in this independent assay system correlated well with the reactivity with chimeric 17-1A.

In addition, we have been able to demonstrate that in patients who develop antibodies to the variable region of 17-1A, a component of this immune response was able to inhibit the binding of 17-1A to tumor cell targets. This component of the anti-idiotypic response is presumably directed against the 17-1A combining site and may consequently mimic the 17-1A antigen (mirror-image anti-idiotypic antibody).

Our results indicate that the enhancement of effector function and tumor antigen expression that has been associated with IFN $\gamma$  in vitro [4, 20, 25, 29, 31] and in vivo [22, 32] did not translate into therapeutic effectiveness in this combined therapy strategy. The median survival observed in our current study is identical to that obtained with 17-1A alone, the survival curves being nearly superimposable (Fig. 2). The dose and schedule of 17-1A maintained a serum concentration of more than 10  $\mu$ g/ml for a duration of 10 days. The dose and type of IFN $\gamma$  were selected upon the basis of previous studies showing in vivo monocyte activation in man [21]. To ensure optimal synergy based

upon in vitro findings, IFN $\gamma$  was administered 5 days prior to and was continued 2 days beyond the duration of 17-1A therapy.

A previous study using the combination of 17-1A and IFN $\gamma$  also reported no clinical responses [32]. This study used a lower dose of 17-1A and a different IFN $\gamma$  preparation, dose and schedule. This led some investigators to imply that improvement in antibody delivery by escalating the therapeutic doses of 17-1A might improve antitumor effects. Our present study indicates that despite the administration of large doses of 17-1A (1.6 g total dose), no clinical responses were achieved. It may be that antibodies with a higher binding affinity or ability to activate other arms of the human immune system (e.g., complement activation) need to be developed in order to enhance the in vivo effect. The use of genetically engineered monoclonal reagents with a greater ability to circulate [16], reduced immunogenicity [15] and enhanced biological activity [13] may improve in vivo efficacy. Dramatic responses in patients with non-Hodgkin's lymphoma have been achieved using such reagents [5]. Finally, several additional reagents to improve antibody-dependent cellular cytotoxicity, including interleukin-2 [26] and growth factors like granulocyte/macrophage and macrophage colony-stimulating factors [18, 28], are appropriate for studying in combination with monoclonal antibodies.

## References

1. Balch CM, Tilden AB, Dougherty PA, Cloud GA, Abo T (1984) Heterogeneity of natural killer lymphocyte abnormalities in colon cancer patients. *Surgery USA* 95: 63
2. Ernstoff MS, Kirkwood JM (1984) Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. *Am J Med* 76: 593
3. Foon KA, Schroff RW, Bunn PA, Mayer D, Abrams PG, Fer M, Ochs J, Bottino GC, Sherwin SA, Carlo DJ (1984) Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. *Blood* 64: 1085
4. Greiner JW, Hand PW, Noguchi P, Fisher PB, Pestka S, Schlom J (1984) Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant leukocyte  $\alpha$ -interferon treatment. *Cancer Res* 44: 3208
5. Hale G, Clark MR, Marcus R, Winter G, Dyer MJS, Phillips JM, Riechmann L, Waldmann H (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody compath-1H. *Lancet*, 1394
6. Herlyn D, Herlyn M, Steplewski Z, Koprowski H (1979) Monoclonal antibody in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. *Eur J Immunol* 9: 657
7. Jain RK (1987) Transport of molecules in the tumor interstitium: a review. *Cancer Rep* 47: 3039
8. Kerbel RJ (1979) Implications of immunological heterogeneity of tumors. *Nature* 280: 358
9. Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, Carranto R, LoBuglio AF (1988) Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A: II. Pharmacokinetics and immune response. *JNCI* 80: 937
10. Koprowski H, Herlyn D, Lubeck M, Defreitas E, Sears HF (1984) Human anti-idiotypic antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? *Proc Natl Acad Sci USA* 81: 216

11. Kurzrock R, Quesada JR, Talpaz M, Hersh EM, Reuben JM, Sherwin SA, Gutterman JU (1986) Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. *J Clin Oncol* 4: 1101
12. Laszlo J, Huang AT, Brenckman WD, Jeffs C, Koren H, Cianciolo G, Metzgar R, Cashdollar W, Cox E, Buckley CE III, Tso CY, Lucas VS Jr (1983) Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer. *Cancer Res* 43: 4458
13. Liu A, Robinson R, Murray E, Ledbetter J, Hellström I, Hellström K (1987) Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. *J Immunol* 139: 3521
14. LoBuglio AF, Khazaeli MB, Lee J, Haynes A, Sumerel L, Mischak R, Spitzer L (1988) Pharmacokinetics and immune response to xomazyme-mel in melanoma patients. *Antibody Immunoconjugate Radiopharmacol* 1: 305
15. LoBuglio AF, Saleh MN, Lee J, Khazaeli MB, Carrano R, Holden H, Wheeler RH (1988) Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A: I. Clinical aspects. *JNCI* 80: 932
16. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghayeb J, Khazaeli MB (1989) Mouse/human chimeric monoclonal antibody in man: kinetic and immune response. *Proc Natl Acad Sci USA* 86: 4220
17. Mecker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R (1985) A clinical trial of anti-idiotypic therapy for B cell malignancy. *Blood* 65: 1349
18. Metcalf D (1986) The molecular biology and function of granulocyte-macrophage colony-stimulating factors. *Blood* 67: 257
19. Miller RA, Maloney DG, Warnke R, Levy R (1982) Treatment of a B cell lymphoma with monoclonal anti-idiotypic antibody. *N Engl J Med* 306: 517
20. Murray HW (1988) Interferon gamma, the activated macrophage, and host defense against microbial challenge. *Ann Int Med* 108: 595
21. Nathan CF, Horowitz CR, de la Harpe J, Vadhan-Raj S, Sherwin SA, Oettgen HF, Krown SE (1985) Administration of recombinant interferon  $\gamma$  to cancer patients enhances monocyte secretion of hydrogen peroxide. *Proc Natl Acad Sci USA* 82: 8686
22. O'Connell MJ, Ritts RA Jr, Moertel CG, Schutt AJ, Sherwin SA (1989) Recombinant interferon- $\gamma$  lacks activity against metastatic colorectal cancer but increases serum levels of Ca 19-9. *Cancer* 63: 1998
23. Schroff RW, Stevenson HC (1985) Human immune responses to murine monoclonal antibodies. In: Foon KA, Morgan AC (eds) *Monoclonal antibody therapy of human cancer*. Nijhoff, The Hague, p 121
24. Sears HG, Herlyn D, Steplewski Z, Koprowski H (1984) Effects of monoclonal antibody immunotherapy in patients with gastrointestinal adenocarcinoma. *J Biol Response Modif* 3: 138
25. Skoskiewicz MJ, Colvin RB, Schneegerger EE, Russell PS (1985) Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by  $\gamma$  interferon. *J Exp Med* 162: 1645
26. Smith KA (1988) Interleukin-2: Inception, impact and implications. *Science* 240: 1169
27. Steplewski Z, Lubeck MD, Koprowski H (1983) Human macrophages armed with murine immunoglobulin gamma 2a antibodies to tumors destroy human cancer cells. *Science* 221: 865
28. Suzu S, Yokota H, Yamada M, Yanai N, Saito M, Kawashima T, Saito M, Takaku F, Motoyoshi K (1989) Enhancing effect of human monocytic colony-stimulating factor on monocyte tumoricidal activity. *Cancer Res* 49: 5913
29. Tweardy DJ, Fujiwara H, Scillian JJ, Ellner J (1986) Concurrent enhancement of monocyte immunoregulatory properties and effector functions by recombinant interferon- $\gamma$ . *Cell Immunol* 100: 34
30. Vadhan-Ray S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN (1988) Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. *J Clin Oncol* 6: 1636
31. Wallach D, Fellous M, Revel M (1982) Preferential effect of  $\gamma$ -interferon on the synthesis of HLA antigens and their mRNAs in human cells. *Nature* 299: 833
32. Weiner LM, Moldofsky PJ, Gatenby RA, O'Dwyer J, O'Brien J, Litwin S, Comis RL (1988) Antibody delivery and effector cell activation in a phase II trial of recombinant  $\gamma$ -interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma. *Cancer Res* 48: 2568